Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 56.17% | -21.97% | -5.61% | -77.12% | 75.27% |
| Total Depreciation and Amortization | 66.67% | 152.38% | 152.38% | 7.23% | -61.59% |
| Total Amortization of Deferred Charges | 100.73% | 44.45% | 23.09% | 2.50% | -11.73% |
| Total Other Non-Cash Items | -75.74% | -74.04% | -75.33% | 33.24% | 49.52% |
| Change in Net Operating Assets | 75.81% | 58.53% | -195.13% | -2,307.48% | -542.63% |
| Cash from Operations | 44.65% | -262.17% | -1,174.10% | -266.66% | 82.54% |
| Capital Expenditure | -- | 100.00% | -11.33% | -234.25% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -11.33% | -101.40% | -100.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 73.86% | -- | -- | -- | -- |
| Issuance of Common Stock | -7.25% | -88.25% | -97.05% | -91.26% | 60.75% |
| Repurchase of Common Stock | -- | 99.99% | 99.99% | -1,718,885.00% | -1,718,885.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.67% | -51.55% | -55.76% | 2,477.33% | 2,906.61% |
| Cash from Financing | -58.16% | -26.70% | -65.01% | -112.69% | 71.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.06% | -274.91% | -303.10% | -237.06% | 247.00% |